Continuous and semi-continuous cell culture for production of blood clotting factors.
| Autor: | Desai SG; Manufacturing Sciences and Technology, Pfizer, One Burtt Road, Andover, MA 01810, USA. Electronic address: sunil.desai@pfizer.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of biotechnology [J Biotechnol] 2015 Nov 10; Vol. 213, pp. 20-7. Date of Electronic Publication: 2015 Mar 01. |
| DOI: | 10.1016/j.jbiotec.2015.02.021 |
| Abstrakt: | Recombinant clotting factors are important biotherapeutics that Pfizer has produced and marketed for over fifteen years. Owing to the complexity of the structure and function of these blood factors, it can be challenging to achieve the required product quality and manufacturing productivity. The article highlights the semi-continuous and continuous cell culture processes employed by Pfizer for the production of BeneFIX and ReFacto AF. The benefits of such processes, the challenges of maintaining an aseptic production culture for extended periods, and batch definition are discussed in this article. (Copyright © 2015 Elsevier B.V. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect